# OLUMIANT — FDA application NDA207924

Informational only - not investment advice.

Application NDA207924 · type NDA · FDA status: approved · original approval 2018-05-31

Listed sponsor: ELI LILLY AND CO · [LLY company profile](/company/LLY/) · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

## FDA application facts

| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 001 | OLUMIANT | BARICITINIB | TABLET | ORAL | 2MG | Prescription | AB | Yes |
| 002 | OLUMIANT | BARICITINIB | TABLET | ORAL | 1MG | Prescription | AB | Yes |
| 003 | OLUMIANT | BARICITINIB | TABLET | ORAL | 4MG | Prescription | AB | Yes |

## Orange Book patent and exclusivity listings

- Patent 8420629, product 001; listed patent expiry date: 2029-03-10.
- Patent 8420629, product 002; listed patent expiry date: 2029-03-10.
- Patent 11806555, product 001; listed patent expiry date: 2031-11-02.
- Patent 11806555, product 002; listed patent expiry date: 2031-11-02.
- Patent 11806555, product 003; listed patent expiry date: 2031-11-02.
- Patent 9737469, product 001; listed patent expiry date: 2031-11-02.
- Patent 9737469, product 002; listed patent expiry date: 2031-11-02.
- Patent 9737469, product 003; listed patent expiry date: 2031-11-02.
- Patent 8158616, product 001; listed patent expiry date: 2032-05-31.
- Patent 8158616, product 002; listed patent expiry date: 2032-05-31.
- Patent 8158616, product 003; listed patent expiry date: 2032-05-31.
- Patent 11045474, product 001; listed patent expiry date: 2032-11-30.
- Patent 11045474, product 002; listed patent expiry date: 2032-11-30.
- Patent 11045474, product 003; listed patent expiry date: 2032-11-30.
- Patent 9089574, product 001; listed patent expiry date: 2032-11-30.
- Patent 9089574, product 002; listed patent expiry date: 2032-11-30.
- Patent 9089574, product 003; listed patent expiry date: 2032-11-30.

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

## Compound cross-links

- BARICITINIB · UNII ISP4442I3Y · [lmmol compound XUZMWHLSFXCVMG-UHFFFAOYSA-N](https://lmmol.com/compound/XUZMWHLSFXCVMG-UHFFFAOYSA-N)

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

## Related pages

- [Sponsor company](/company/LLY/)
- [FDA-approved application index](/drug/)
- [Large-cap biopharma](/compare/pharma/)

Sources: https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files · https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files · https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA207924. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.